Clinical Trials Logo

Hepatitis clinical trials

View clinical trials related to Hepatitis.

Filter by:

NCT ID: NCT03343444 Enrolling by invitation - Clinical trials for Hepatitis C Virus Infection, Response to Therapy of

Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents

Start date: April 15, 2017
Phase: Phase 3
Study type: Interventional

Randomized, open-label study in treatment naïve and treatment experienced, adolescence to determine the efficacy of Sofosbuvir 400mg/ledipasvir 90mg in treatment naïve and treatment-experienced adolescence. Hepatitis C virus (HCV) infection as measured by the proportion of subjects with sustained viral response 12 weeks after discontinuation of therapy (SVR12)

NCT ID: NCT03343431 Active, not recruiting - Pregnancy Clinical Trials

Antiviral Prophylaxis and Infant Vaccination to Prevent Perinatal Hepatitis B Infection

Start date: August 2, 2018
Phase: Phase 3
Study type: Interventional

Most new hepatitis B virus (HBV) infections are acquired perinatally. In this study, pregnant women with HBsAg and HBeAg will receive tenofovir disoproxil fumarate during the last trimester of pregnancy and for two months following delivery. Their infants will receive hepatitis B (HB) immunization, starting with a first dose soon after birth. We hypothesize that the risk of mother-to-child transmission of HBV will be lower than 2%. The results of the study will help define policy to manage HBV infected pregnant women to prevent perinatal transmission.

NCT ID: NCT03342261 Completed - Clinical trials for Hepatitis C, Chronic

Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia

Start date: March 1, 2017
Phase: N/A
Study type: Observational

Mixed cryoglobulinemia (MC) is common in patients with chronic hepatitis C virus (HCV) infection. Direct-acting antiviral (DAA) regimens are today very effective with sustained virological response rates (SVR12) above 90%. The objective of this study was to investigate the impact of DAA therapy on cryoglobulin clearance in patients with HCV-associated MC.

NCT ID: NCT03341871 Completed - Clinical trials for Hepatitis C Virus (HCV)

Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6

Start date: December 27, 2017
Phase:
Study type: Observational

This multi-center, post-marketing, observational study evaluates the real world safety and effectiveness of glecaprevir plus pibrentasvir use in participants infected with the hepatitis C virus genotype 1 - 6.

NCT ID: NCT03332329 Active, not recruiting - Chronic Hepatitis b Clinical Trials

Sequential/Combination Therapy in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients

NPGV
Start date: December 1, 2015
Phase: Phase 4
Study type: Interventional

The aim of the prospective study is to determine whether combination/ sequential therapy with Entecavir, Peginterferon alfa-2b and immunomodulators Granulocyte Macrophage Colony Stimulating Factor (GMCSF)+vaccine could induce HBsAg loss in chronic hepatitis B patients with maintained Hepatitis B Virus (HBV) DNA suppression on long-term nucleoside or nucleotide analogue (NA).

NCT ID: NCT03330171 Active, not recruiting - Measles Clinical Trials

Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine

MV/VV/Hep-AV
Start date: April 10, 2017
Phase: Phase 4
Study type: Interventional

This trial will evaluate the safety and immunogenicity of: i) measles vaccine (CAM-70) after primary dose at 6 months (MV1) and booster vaccination at 12 months (MV2); ii) a single dose of varicella vaccination at 18 months; and iii) a single dose of hepatitis-A vaccination at 18 months in HIV-exposed and HIV-unexposed South African children.

NCT ID: NCT03329820 Completed - Clinical trials for Chronic Hepatitis B Infection

Quality of Life and Health Utility of Patients With CHB Infections

Start date: November 2006
Phase: N/A
Study type: Observational

The aim of the study is to assess the health-related quality of life (HRQOL) and preference-based health utilities of chronic hepatitis B (CHB) carriers in different stages of illness. It will also estimate the cost-effectiveness of anti-viral treatments resulting from the prevention of the progression of disease from uncomplicated CHB carriers to cirrhosis and hepatocellular carcinoma (HCC). The following hypotheses will be tested: 1. Patients with chronic hepatitis B virus (HBV) have poorer health-related quality of life (HRQOL) than the general population; 2. Patients with more severe stages of chronic HB infections have lower health related quality of life and health utility values; 3. Anti-viral treatment can improve the HRQOL and health utility for patients with CHB infections; 4. The cost-effectiveness of different treatments for chronic HBV infections can be directly compared in terms of cost/QALY gained.

NCT ID: NCT03324633 Completed - HIV Clinical Trials

Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV

CO13Hepavih
Start date: June 2005
Phase:
Study type: Observational

The ANRS CO13 HEPAVIH cohort is a prospective and multicentric cohort created in 2005 with the originality to cover two therapeutic domains of key importance, AIDS and hepatitis C. The cohort, is unique in Europe with more than 1800 participants followed over 10 years including quality of life and compliance to treatment data.

NCT ID: NCT03320889 Completed - Hepatitis C Clinical Trials

Hepatitis C Education for Pregnant Women With Opiate Dependence - Phase 2

Start date: October 30, 2017
Phase: N/A
Study type: Interventional

The goal of this study is to assess patients' attitudes and knowledge of Hepatitis C, analyze the variables that may influence patients' knowledge, and educate patients on Hepatitis C.

NCT ID: NCT03320616 Completed - Clinical trials for Hepatitis B, Chronic

EYP001a Food Effect Study in Subjects With Chronic Hepatitis B Virus (HBV) Infection

Start date: February 10, 2017
Phase: Phase 1
Study type: Interventional

The farnesoid X receptor (FXR) regulates hepatitis B virus replication through the bile acids pathway. EYP001a is a selective, synthetic FXR agonist under development for the treatment of hepatitis B. This Phase 1 study is designed primarily to assess Pharmacokinetics (PK) under fed and fasted conditions, and to assess the safety, tolerability and Pharmacodynamics (PD) of single oral doses of EYP001a in subjects with chronic HBV infection.